The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A propensity score matching analysis

Byun, Hye Jin; Shin, Teak Jun; Jung, Wonho; Ha, Ji Yong; Kim, Byung H.; Kim, Young H.

doi:10.1016/j.prnil.2021.10.002

Cited by 6 publications

(15 citation statements)

References 22 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies indicated that MRI‐guided prostate biopsy helps improve the detection rate of PCa in prostate biopsies from patients with PSA levels within 4–10 ng/mL. Bang et al, 38 Byun et al, 37 and Sönmez et al 21 applied the PI‐RADS scoring system for the interpretation of MRI results, and all three studies performed targeted biopsies in cases with PI‐RADS 3 to 5. Byun et al 37 used the bpMRI‐based PI‐RADS v2.1 scoring system for prostate lesions, then performed targeted biopsies of lesions with PI‐RADS 3–5 by the software‐based MRI‐TRUS fusion system and compared the efficacy of MRI‐TRUS fusion biopsies with TRUS‐guided biopsies for csPCa detection.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies 16,23,30,33,39 used 1 H MRS sequences in combination with other conventional sequences and 1 study 22 used only T2WI. With regard to MRI image interpretation, 12 studies 21,[24][25][26]28,29,31,32,34,[36][37][38] used the Prostate Imaging Reporting and Data System (PI-RADS) score. Out of these 12 studies, 10 used the PI-RADS v2 and 2 studies 31,37 used the PI-RADS v2.1.…”

Section: Mr Characteristicsmentioning

confidence: 99%

“…26,32,33 Out of the 11 studies that used MRI-guided biopsy, eight used cognitive fusion biopsy, ,20,23,28,29,31,34,35 two used software-assisted fusion biopsy, 21,36 and one used MRI-directed biopsy. 37 In addition, two studies 30,38 used MRS imaging (MRSI)-directed TRUSguided biopsy.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The samples in 15 studies 19,[21][22][23][24][25][26][27][28][29][30][31][32][33]35 consisted exclusively of patients with PSA between 4 ng/mL and 10 ng/mL, while a group of patients with PSA levels within the gray zone was only one of the several groups of study samples in seven studies. 17,20,34,[36][37][38][39] With regard to study objectives, 6 of the 23 (26.1%) studies 19,21,30,[37][38][39] focused on the role of MRI or MRS in guiding prostate biopsy, and the remaining studies focused on the applicability of MRI or MRS for predicting prostate biopsy results. Eleven articles further investigated the detection of clinically significant PCa (csPCa) [24][25][26]31,[33][34][35]37,38 or high-grade PCa (HGPCa) 29,32 by MRI or MRS, which showed large heterogeneity across studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Patients With “Gray Zone” PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer

Chen

2022

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Improving the detection rates of prostate cancer (PCa) and avoiding unnecessary prostate biopsies in men with prostate‐specific antigen (PSA) levels within the gray zone require urgent attention. In this context, rapid advances in MR technology in recent years may offer a promising possibility. A systematic review to evaluate the applications of magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in detecting PCa and clinically significant PCa (csPCa) in men with PSA levels within the gray zone. The study type is defined as systematic review. In July 2022, out of 229 studies identified by the database search and from other sources, 23 articles related to the selected topic of interest were included in this review. No field strength or sequence restrictions. The data including the study population, study characteristics, as well as basic MRI characteristics, from the final studies included in this review, were extracted independently by two reviewers. The major results of the original study were summarized and no additional statistical analysis was performed. Among the 23 studies included in this review, 17 focused on the applications of MRS and MRI for the prebiopsy diagnosis of PCa. Nine of these 17 articles used Prostate Imaging Reporting and Data System (PI‐RADS) score to interpret MRI results, thereby confirming the practicality of the PI‐RADS score in predicting PCa and csPCa. The remaining six articles evaluated the applications of MRI and MRS in guiding prostate biopsy. Although there was a variation in the biopsy modalities used in these studies, both MRI‐ and MRS‐guided prostate biopsies were observed to improve the detection rates of PCa and csPCa in patients with PSA levels within the gray zone. MRS and MRI showed good performance in the detection of PCa and csPCa before biopsy. In addition, MRS‐ or MRI‐guided prostate‐targeted biopsies were able to improve the detection rates of PCa and csPCa. Evidence Level 3 Technical Efficacy Stage 2

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Mr Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Patients With “Gray Zone” PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer

Chen

2022

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…It is used as an important biomarker for diagnosing prostate cancer by measuring its concentration in blood samples [ 11 ]. Serum PSA concentrations between 4.0 and 10.0 ng/mL are considered normal; a concentration of PSA more than 10.0 ng/mL is indicative of a carcinoma of the prostate in its first stages [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Prostate-Specific Antigen Monitoring Using Nano Zinc(II) Metal–Organic Framework-Based Optical Biosensor

et al. 2022

View full text Add to dashboard Cite

Background: The prostate-specific antigen (PSA) is an important cancer biomarker that is commonly utilized in the diagnosis of prostate cancer. The development of a PSA determination technique that is rapid, simple, and inexpensive, in addition to highly accurate, sensitive, and selective, remains a formidable obstacle. Methods: In this study, we developed a practical biosensor based on Zn(II) metal–organic framework nanoparticles (Zn-MOFs-NPs). Many spectroscopic and microanalytical tools are used to determine the structure, morphology, and physicochemical properties of the prepared MOF. Results: According to the results, Zn-MOFs-NPs are sensitive to PSA, selective to an extremely greater extent, and stable in terms of chemical composition. Furthermore, the Zn-MOFs-NPs did not exhibit any interferences from other common analytes that might cause interference. The detection limit for PSA was calculated and was 0.145 fg/mL throughout a wide linear concentration range (0.1 fg/mL–20 pg/mL). Conclusions: Zn-MOFs-NPs were successfully used as a growing biosensor for the monitoring and measurement of PSA in biological real samples.

show abstract

Irreversible electroporation for prostate cancer using PSMA PET-CT

Shin

Yoon

Kwon

et al. 2023

Prostate International

View full text Add to dashboard Cite

The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A propensity score matching analysis

Cited by 6 publications

References 22 publications

Patients With “Gray Zone” PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer

Patients With “Gray Zone” PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer

Prostate-Specific Antigen Monitoring Using Nano Zinc(II) Metal–Organic Framework-Based Optical Biosensor

Irreversible electroporation for prostate cancer using PSMA PET-CT

Contact Info

Product

Resources

About